Background: Transfusion support after allogeneic transplantation is closely associated with morbidity, cost and may also affect long-term outcome. To better predict the determinants of hematopoietic recovery of allogeneic hematopoietic stem cell transplantation (HSCT) recipients, we analyzed 214 consecutive patients at our institution from January 2012 to December 2013. Patients and methods: We evaluated surrogate parameters for adequate hematopoietic recovery on day 100: Hemoglobin ≥10 g/dl, packed red blood cells (PRBCs) transfusion independence, platelets transfusion independence and independence from granulocyte colony stimulating factor (GCSF) support. We excluded patients who experienced early (in the first 4 months) relapse (n = 28), non-relapse mortality (n = 28) or who had prolonged hospital stay before day 100 for transplant related complications (n = 54). One hundred and four patients had uneventful recovery through day 100. The majority of patients received Fludarabine and melphalan conditioning (88%). Approximately one third each of the patients had HLA-identical related, HLA-matched unrelated donors or underwent haplo-cord transplantation. Recipients of HLA-identical related or unrelated donor transplant received alemtuzumab and post-transplant tacrolimus. Haplo-cord recipients received thymoglobulin and post-transplant tacrolimus and mycophenolate. The statistical analyses were performed using STATA v14.1 (Stata Corp, TX, USA). Continuous variables were compared using two-sided t-tests and categorical variables were compared using Pearson c2 and Fisher's exact tests. Differences were considered significant at P-values < .05. Results: There was a significant and marginally significant correlation between Major ABO incompatibility and platelets (OR = 4.7, P = .043) and PRBCs (OR = 2.6, P = .053) transfusion dependence. CMV viremia significantly correlated with GCSF dependency (OR 3.0, P = .037), while acute GVHD significantly correlated with prolonged anemia (OR 3.7, P = .005). There was no effect of graft type alone on hematopoietic recovery. Conclusion: Major ABO incompatibility, CMV viremia and acute GVHD are major predictors of prolonged hematopoietic recovery. Hematopoietic recovery of umbilical cord blood is similar to adult matched related and unrelated grafts.